Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GENZ results give pause

GENZ results give pause

Genzyme Corp. reported an improved quality of life with its Thyrogen recombinant thyroid stimulating hormone (TSH) as a scanning aid for detecting thyroid cancer. But GENZ is holding off on filing an NDA until meeting with the FDA next month. The glitch is that a few percent of patients did not have their recurrent disease show

Read the full 606 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers